Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

KRAS mutations are associated with specific morphologic features in colon cancer.

Gunal A, Hui P, Kilic S, Xu R, Jain D, Mitchell K, Robert M, Kenney B.

J Clin Gastroenterol. 2013 Jul;47(6):509-14. doi: 10.1097/MCG.0b013e3182703030.

PMID:
23090042
2.

BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.

Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, Pai RK.

Am J Surg Pathol. 2012 May;36(5):744-52. doi: 10.1097/PAS.0b013e31824430d7.

PMID:
22314188
3.

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F.

J Clin Oncol. 2010 Jan 20;28(3):466-74. doi: 10.1200/JCO.2009.23.3452. Epub 2009 Dec 14.

PMID:
20008640
4.
5.

Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.

Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK.

Mod Pathol. 2012 Aug;25(8):1128-39. doi: 10.1038/modpathol.2012.61. Epub 2012 Apr 6.

6.

Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.

Marotti JD, Schwab MC, McNulty NJ, Rigas JR, DeLong PA, Memoli VA, Tsongalis GJ, Padmanabhan V.

Diagn Cytopathol. 2013 Jan;41(1):15-21. doi: 10.1002/dc.21749. Epub 2011 Jun 16.

PMID:
21681971
7.

[KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese].

Zhu XL, Cai X, Zhang L, Yang F, Sheng WQ, Lu YM, Du X, Zhou XY.

Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):584-9. doi: 10.3760/cma.j.issn.0529-5807.2012.09.003. Chinese.

PMID:
23157824
8.

KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype.

Kim KM, Lee EJ, Kim YH, Chang DK, Odze RD.

Am J Surg Pathol. 2010 May;34(5):667-75. doi: 10.1097/PAS.0b013e3181d40cb2.

PMID:
20305537
9.

Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.

Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS.

J Pathol. 2009 Dec;219(4):435-45. doi: 10.1002/path.2625.

PMID:
19824059
10.

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.

Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, Yoshino T.

BMC Cancer. 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z.

11.

Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Cushman-Vokoun AM, Stover DG, Zhao Z, Koehler EA, Berlin JD, Vnencak-Jones CL.

Clin Colorectal Cancer. 2013 Sep;12(3):168-78. doi: 10.1016/j.clcc.2013.04.005. Epub 2013 Jun 14.

12.

Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.

Cserepes M, Ostoros G, Lohinai Z, Raso E, Barbai T, Timar J, Rozsas A, Moldvay J, Kovalszky I, Fabian K, Gyulai M, Ghanim B, Laszlo V, Klikovits T, Hoda MA, Grusch M, Berger W, Klepetko W, Hegedus B, Dome B.

Eur J Cancer. 2014 Jul;50(10):1819-28. doi: 10.1016/j.ejca.2014.04.001. Epub 2014 Apr 22.

13.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

14.

The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.

Izar B, Zhou H, Heist RS, Azzoli CG, Muzikansky A, Scribner EE, Bernardo LA, Dias-Santagata D, Iafrate AJ, Lanuti M.

J Thorac Oncol. 2014 Sep;9(9):1363-9. doi: 10.1097/JTO.0000000000000266.

15.

Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.

Benedix F, Meyer F, Kube R, Kropf S, Kuester D, Lippert H, Roessner A, Krüger S.

Pathol Res Pract. 2012 Oct 15;208(10):592-7. doi: 10.1016/j.prp.2012.07.003. Epub 2012 Aug 13.

PMID:
22898351
16.

Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.

Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, Tsuruyama T, Travis WD, Date H, Haga H.

J Thorac Oncol. 2013 Jan;8(1):52-61. doi: 10.1097/JTO.0b013e3182769aa8.

17.

Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients.

Revuelta I, Moya-Rull D, García-Herrera A, Rovira J, Ayala de la Peña F, Misiego A, Guzmán F, Oppenheimer F, Albanell J, Campistol JM.

Transplantation. 2012 Mar 15;93(5):509-17. doi: 10.1097/TP.0b013e318242be46.

PMID:
22245873
18.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL.

J Clin Oncol. 2009 Apr 20;27(12):2091-6. doi: 10.1200/JCO.2009.21.9170. Epub 2009 Feb 2. Review.

PMID:
19188670
19.

[Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].

Gao J, Sun ZW, Li YY, Shen L.

Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):579-83. doi: 10.3760/cma.j.issn.0529-5807.2012.09.002. Chinese.

PMID:
23157823
20.

Supplemental Content

Support Center